keyword
MENU ▼
Read by QxMD icon Read
search

Nonsmall lung cancer

keyword
https://www.readbyqxmd.com/read/29038154/deactivated-crispr-associated-protein-9-for-minor-allele-enrichment-in-cell-free-dna
#1
Amin Aalipour, Jonathan C Dudley, Seung-Min Park, Surya Murty, Jacob J Chabon, Evan A Boyle, Maximilian Diehn, Sanjiv S Gambhir
BACKGROUND: Cell-free DNA (cfDNA) diagnostics are emerging as a new paradigm of disease monitoring and therapy management. The clinical utility of these diagnostics is relatively limited by a low signal-to-noise ratio, such as with low allele frequency (AF) mutations in cancer. While enriching for rare alleles to increase their AF before sample analysis is one strategy that can greatly improve detection capability, current methods are limited in their generalizability, ease of use, and applicability to point mutations...
October 16, 2017: Clinical Chemistry
https://www.readbyqxmd.com/read/29033676/the-role-of-fluorodeoxy-d-glucose-positron-emission-tomography-computed-tomography-in-nodal-staging-of-nonsmall-cell-lung-cancer-in-sequential-surgical-algorithm
#2
Yuyang Zhang, Yolanda Elam, Patricia Hall, Hadyn Williams, Darko Pucar, Vijay Patel
With nonsmall cell lung cancer (NSCLC), accurate mediastinal nodal staging is crucial to determine whether a patient is or is not a surgical candidate. Traditionally, computed tomography (CT) and fluorodeoxy-D-glucose (FDG) positron emission tomography (PET)/CT are the initial steps followed by tissue sampling through mediastinoscopy and/or thoracotomy, which are invasive procedures. There is controversy regarding the possibility of omission of the invasive diagnostic procedures and solely relying on noninvasive presurgical staging CT and FDG PET/CT results...
October 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29024297/reducing-dose-to-the-lungs-through-loosing-target-dose-homogeneity-requirement-for-radiotherapy-of-non-small-cell-lung-cancer
#3
Junjie Miao, Hui Yan, Yuan Tian, Pan Ma, Zhiqiang Liu, Minghui Li, Wenting Ren, Jiayun Chen, Ye Zhang, Jianrong Dai
It is important to minimize lung dose during intensity-modulated radiation therapy (IMRT) of nonsmall cell lung cancer (NSCLC). In this study, an approach was proposed to reduce lung dose by relaxing the constraint of target dose homogeneity during treatment planning of IMRT. Ten NSCLC patients with lung tumor on the right side were selected. The total dose for planning target volume (PTV) was 60 Gy (2 Gy/fraction). For each patient, two IMRT plans with six beams were created in Pinnacle treatment planning system...
October 11, 2017: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28980429/metabolic-characteristics-of-programmed-cell-death-ligand-1-expressing-lung-cancer-on-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography
#4
Kazuki Takada, Gouji Toyokawa, Tatsuro Okamoto, Shingo Baba, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Takaki Akamine, Shinkichi Takamori, Masakazu Katsura, Fumihiro Shoji, Hiroshi Honda, Yoshinao Oda, Yoshihiko Maehara
Programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have been identified as novel targets of immunotherapy of lung cancer. In present study, we evaluated the metabolic characteristics of lung cancer by using (18) F-fluorodeoxyglucose positron emission tomography/computed tomography ((18) F-FDG PET/CT) with regard to PD-L1 protein expression. PD-L1 protein expression was evaluated by immunohistochemistry with the antibody clone SP142 in 579 surgically resected primary lung cancer patients...
October 4, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28968265/diagnostic-utility-of-pd-l1-expression-in-lung-adenocarcinoma-immunohistochemistry-and-rna-in-situ-hybridization
#5
Mohamad Mazen Gafeer, Kareem Hosny Mohammed, Claudia Ormenisan-Gherasim, Fahad Choudhary, Momin T Siddiqui, Cynthia Cohen
BACKGROUND: Programmed death receptor and programmed death ligand (PD-L1) are immunoregulatory proteins. Nonsmall cell lung cancer bypasses the immune system through the induction of protumorigenic immunosuppressive changes. The better understanding of immunology and antitumor immune responses has brought the promising development of novel immunotherapy agents like programmed death receptor checkpoint inhibitors. The aim of this study was to investigate the expression of PD-L1 in lung adenocarcinoma (ADC), comparing 2 different technologies: immunohistochemistry (IHC) by 2 methods versus RNA in situ hybridization (RISH)...
September 29, 2017: Applied Immunohistochemistry & Molecular Morphology: AIMM
https://www.readbyqxmd.com/read/28953659/clinicopathological-radiographic-and-oncogenic-features-of-primary-pulmonary-enteric-adenocarcinoma-in-comparison-with-invasive-adenocarcinoma-in-resection-specimens
#6
Long Zhao, Shanshan Huang, Jinjun Liu, Juan Zhao, Qiang Li, Huo-Qiang Wang
Primary pulmonary enteric adenocarcinoma (PEAC) is a rare subtype of primary lung adenocarcinoma. However, it is not known whether there are any distinctive clinical or molecular features.PEACs were retrospectively identified in 28 patients from July 2014 to June 2016. We compared the clinicopathological, radiographic, and oncogenic characteristics of PEAC and primary pulmonary invasive adenocarcinoma (IAC).A total of 28 PEAC patients and 92 IAC patients were compared. PEAC occurred more frequently in males (P = ...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28953040/novel-therapeutic-agents-in-the-management-of-brain-metastases
#7
Vyshak A Venur, Manmeet S Ahluwalia
PURPOSE OF REVIEW: This review aims to highlight the novel therapeutic agents in the management of brain metastases which are in various stages of clinical development. We review the results from recent clinical trials, publications and presentations at recent national and international conferences. RECENT FINDINGS: Several new systemic treatment options for brain metastases are in early or advanced clinical trials. These drugs have good intracranial and extracranial activities...
August 4, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28901317/k-ras-mutation-and-resistance-to-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitor-treatment-in-patients-with-nonsmall-cell-lung-cancer
#8
Bin Zhou, Congrong Tang, Jie Li
OBJECTIVE: The aim of this study was to evaluate the relationship between k-RAS gene mutation and the resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with nonsmall-cell lung cancer (NSCLC). METHODS: Forty-five pathologies confirmed NSCLC patients who received EGFR-TKI (Gefitinib) treatment were retrospectively included in this study. The mutation of codon 12 and 13, located in exon1 and exon 2 of k-RAS gene were examined by polymerase chain reaction (PCR) and DAN sequencing in tumor samples of the included 45 NSCLC patients...
2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28901314/repeated-percutaneous-microwave-ablation-for-local-recurrence-of-inoperable-stage-i-nonsmall-cell-lung-cancer
#9
Xia Yang, Xin Ye, Guanghui Huang, Xiaoying Han, Jiao Wang, Wenhong Li, Zhigang Wei, Min Meng
BACKGROUND: The safety and effectiveness of repeated computed tomography-guided percutaneous microwave ablation (MWA) in the management of local recurrence (LR) in patients with medically inoperable Stage I nonsmall cell lung cancer (NSCLC) were retrospectively evaluated. MATERIALS AND METHODS: From February 2008 to August 2014, 104 patients with medically inoperable Stage I NSCLC received MWA. Patients with LR were given repeat MWA. The clinical outcomes and complications of repeat MWA for LR were evaluated...
2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28901311/overexpression-of-kiaa1199-an-independent-prognostic-marker-in-nonsmall-cell-lung-cancer
#10
Fei Deng, Jie Lei, Xueqin Zhang, Weiwei Huang, Yongjun Li, Dehua Wu
OBJECTIVE: KIAA1199 has been identified as an oncogene in many cancers. Here, we collected 153 cases of nonsmall cell lung cancer (NSCLC) tissues to investigate the relationships between KIAA1199 protein and clinical factors. MATERIALS AND METHODS: Immunohistochemistry (IHC) staining was used to detect the expression of KIAA1199. Follow-up included blood analysis, chest X-ray, ultrasound examination, and computed tomography was carried out every 3 months for the first 2 years and at 6-month intervals thereafter during the follow-up period (3 years)...
2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28901306/bronchial-artery-chemoembolization-combined-with-radioactive-iodine-125-seed-implantation-in-the-treatment-of-advanced-nonsmall-cell-lung-cancer
#11
Yaoyong Chen, Yuwei Li, Yuming Jia, Kaijian Lei, Xinfeng Zhang, Yueyong Cao, Jun Zhu
OBJECTIVE: The aim of this study was to investigate the short-term efficacy and safety of bronchial artery chemoembolization (BACE) combined with radioactive iodine-125 seed implantation in the treatment of nonsmall cell lung cancer (NSCLC). MATERIALS AND METHODS: Sixty-two Stage III-IV NSCLC patients were divided into Groups A and B. Thirty cases were treated with BACE combined with radioactive iodine-125 seed implantation in the Group A and 32 cases were treated with BACE alone in the Group B until disease progression...
2017: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28885863/long-noncoding-rna-bladder-cancer-associated-transcript-1-promotes-the-proliferation-migration-and-invasion-of-nonsmall-cell-lung-cancer-through-sponging-mir-144
#12
Ji-Ru Ye, Liang Liu, Feng Zheng
Nonsmall cell lung cancer (NSCLC) is a type of malignant tumor, accounting for 80% of all lung cancer morbidity. Long noncoding RNA (lncRNA) BLACAT1 (bladder cancer associated transcript 1), also known as linc-UBC1, has been tested to be an oncogenic lncRNA in other cancers. However, the role of BLACAT1 in NSCLC is still unknown. In clinical study, BLACAT1 expression was significantly upregulated in 48 cases of NSCLC tissues compared with adjacent normal tissues, especially in pathological TNM III samples. In NSCLC cells, BLACAT1 expression was also upregulated...
October 2017: DNA and Cell Biology
https://www.readbyqxmd.com/read/28885346/a-case-control-study-of-the-association-between-self-reported-occupational-and-recreational-physical-activity-and-lung-cancer
#13
Fei He, Li-Mei Chen, Wei-Min Xiong, Qiu-Ping Xu, Ren-Dong Xiao, Xu Li, Tao Lin, Lin Cai
This case-control study with a Fujian population investigated whether self-reported occupational and recreational physical activity may be associated with lung cancer.The population comprised 1622 patients with newly diagnosed primary lung cancer and 1622 age- and gender-matched healthy controls.High-intensity occupational physical activity was associated with significantly higher risk of lung cancer (OR = 1.354, 95% CI: 1.068-1.717), especially nonsmall cell lung carcinoma (OR = 1.384, 95% CI: 1.087-1...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28872894/knockdown-of-long-noncoding-rna-small-nucleolar-rna-host-gene-12-inhibits-cell-growth-and-induces-apoptosis-by-upregulating-mir-138-in-nonsmall-cell-lung-cancer
#14
Xiaoyan Wang, Guanbin Qi, Juanjuan Zhang, Jingcan Wu, Nannan Zhou, Lei Li, Jing Ma
Small nucleolar RNA host gene 12 (SNHG12) is a novel long noncoding RNA identified to be upregulated and functions as an oncogene in several cancers. However, the function of SNHG12 and its target genes in modulating nonsmall cell lung cancer (NSCLC) development are rarely reported. In the present study, we validated that SNHG12 was overexpressed, while miR-138 was low-expressed, in NSCLC cells compared with normal human lung epithelial cells. SNHG12 harbored the binding site of miR-138 and inversely regulated the expression miR-138...
September 5, 2017: DNA and Cell Biology
https://www.readbyqxmd.com/read/28840978/phase-ii-study-of-celecoxib-with-docetaxel-chemoradiotherapy-followed-by-consolidation-chemotherapy-docetaxel-plus-cisplatin-with-maintenance-celecoxib-in-inoperable-stage-iii-nonsmall-cell-lung-cancer
#15
Harminder Takhar, Nimit Singhal, Anna Mislang, Raj Kumar, Laurence Kim, Sid Selva-Nayagam, Ken Pittman, Chris Karapetis, Martin Borg, Ian N Olver, Michael P Brown
TITLE: Phase II study of celecoxib with docetaxel chemoradiotherapy (CRT) followed by consolidation chemotherapy docetaxel plus cisplatin with maintenance celecoxib in inoperable stage III nonsmall cell lung cancer. INTRODUCTION: Concurrent CRT has been associated with improvement in absolute 5-year survival by 10% and is the standard of care for inoperable stage III nonsmall cell lung cancer. Preclinical evidence suggests that cyclooxygenase-2 inhibition may increase the efficacy of CRT...
August 25, 2017: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28816968/two-portal-versus-three-port-video-assist-thoracoscopic-surgery-for-early-stage-nonsmall-cell-lung-cancer-a-retrospective-study
#16
Xiaokun Yan, Xiaochun Chen, Guangbin Li, Shaomu Chen
This study was conducted to compare the perioperative outcomes of two-portal and three-port video-assist thoracoscopic surgery (VATS) for early stage nonsmall cell lung cancer.In this retrospective analysis, 279 cases of two-port VATS with a single utility port and 152 cases of three-port VATS performed by our department from October 2010 to December 2014 were collected. The operative time, volume of intraoperative blood loss, number of dissected lymph nodes, volume of postoperative pleural drainage, postoperative extubation time, and duration of postoperative hospitalization were compared between these 2 groups...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28816950/pemetrexed-carboplatin-with-intercalated-icotinib-in-the-treatment-of-patient-with-advanced-egfr-wild-type-lung-adenocarcinoma-a-case-report
#17
Tongpeng Xu, Hao Wu, Shidai Jin, Huang Min, Zhihong Zhang, Yongqian Shu, Wei Wen, Renhua Guo
RATIONALE: Tyrosine kinase inhibitors (TKIs) are known to have greater efficacy in epidermal growth factor receptor (EGFR) mutation nonsmall cell lung cancer (NSCLC). However, about 10% of EGFR wild-type (wt) patients respond to TKIs. PATIENT CONCERNS: Several strategies to increase the efficacy of TKIs in wt NSCLC are the subjects of ongoing investigations. One of them is combining EGFR TKI with intercalated chemotherapy. DIAGNOSES: We describe a patient with EGFR wt NSCLC, who was found with ovarian and lung metastasis, was treated with pemetrexed and intercalated icotinib...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28809453/a-meta-analysis-micrornas-prognostic-function-in-patients-with-nonsmall-cell-lung-cancer
#18
REVIEW
Na Yu, Qingjun Zhang, Qing Liu, Jiayu Yang, Sheng Zhang
Accumulating papers have demonstrated that microRNAs play an important role in the progression of lung cancer, mainly as oncogenic and tumor suppressive. Therefore, microRNAs may influence the survival of lung cancer patients. In this meta-analysis, we evaluated the role of microRNAs in affecting the overall survival in nonsmall cell lung cancer (NSCLC) patients, which may provide valuable information for the treatment of nonsmall cell lung cancer. We used keywords to retrieve literatures from online databases PUBMED, EMBASE and Web of Science and included 12 studies into our investigation according to pre-set criteria...
September 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28798090/egfr-tyrosine-kinase-inhibitors-versus-chemotherapy-in-egfr-wild-type-pre-treated-advanced-nonsmall-cell-lung-cancer-in%C3%A2-daily-practice
#19
Pascale Tomasini, Solenn Brosseau, Julien Mazières, Jean-Philippe Merlio, Michèle Beau-Faller, Jean Mosser, Marie Wislez, L'Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Didier Debieuvre, Fabienne Escande, Virginie Westeel, Clarisse Audigier-Valette, Pascale Missy, Alexandra Langlais, Frank Morin, Denis Moro-Sibilot, Gérard Zalcman, Fabrice Barlesi
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are approved for second-line treatment of EGFR wild-type (EGFR-wt) nonsmall cell lung cancer (NSCLC). However, results from randomised trials performed to compare EGFR-TKIs with chemotherapy in this population did not show any survival benefit. In the era of immunotherapy, many drugs are approved for second-line treatment of EGFR-wt NSCLC and there is a need to reassess the role of EGFR-TKIs in this setting.The Biomarkers France study is a large nationwide cohort of NSCLC patients tested for EGFR mutations...
August 2017: European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology
https://www.readbyqxmd.com/read/28791988/choroidal-metastases-as-the-initial-presentation-of-lung-cancer-a-rare-scenario
#20
S Shamim, S Vidya, Skh Kabir, B Ghosh
Clinical reports of symptomatic intraocular metastasis as the initial presentation of lung cancer are rare. We report the case of a 49-year-old female patient who presented with loss of vision due to choroidal metastases as the initial manifestation of her disseminated lung cancer. This particular patient was referred to us from ophthalmology department as a case of choroidal metastases from unknown primary. Detailed evaluation at our department helped detect the primary to be a nonsmall cell carcinoma of the right lung, which had multiple distant metastases...
July 2017: Nigerian Journal of Clinical Practice
keyword
keyword
55784
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"